Clinical Trials Directory

Trials / Completed

CompletedNCT03124511

Neuropathic Pain After Breast Surgery

DOLORISK: Understanding Risk Factors and Determinants for Neuropathic Pain - Neuropathic Pain After Breast Surgery

Status
Completed
Phase
Study type
Observational
Enrollment
150 (actual)
Sponsor
Danish Pain Research Center · Academic / Other
Sex
Female
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

To understand pain pathophysiology in terms of risk factors and protective mechanisms ranging from molecular pathways to societal impacts.

Detailed description

Pain and loss of function are intimately associated with the reaction of the nervous system to neural damage. A lesion to the somatosensory nervous system caused by mechanical trauma, metabolic disease, neurotoxic chemicals, infection or tumor invasion may give rise to neuropathic pain. Neuropathic pain affects around 8% of the population and may negatively impact the individual's quality of life; moreover, the condition leads to significant costs to the healthcare system and society. Not all subjects with such a lesion develop neuropathic pain, and those who do develop neuropathic pain have varying degrees of symptom severity, impact and outcomes and may respond unpredictably to treatment. The interaction between genetics and environmental and clinical factors in a susceptible individual most likely contribute to the variation in pain prevalence and severity. A better understanding of the exact nature of these risk factors and their interactions will ultimately improve the patients' health, both in terms of recognizing patients at risk and identifying new treatment modalities. Genetic, neurophysiological and psychological factors all influence the risk of developing persistent pain. It is therefore possible to describe a genetic, neurophysiological and psychological profile, in particular in patients experiencing neuropathic pain after surgery and/or neurotoxic chemotherapy.

Conditions

Interventions

TypeNameDescription
PROCEDURESurgery for breast cancerBreast cancer resection performed via lumpectomy or mastectomy with or without sentinal node biopsy and axillary lymph node dissection.

Timeline

Start date
2017-08-15
Primary completion
2021-08-01
Completion
2021-08-01
First posted
2017-04-21
Last updated
2021-08-17

Locations

2 sites across 1 country: Denmark

Source: ClinicalTrials.gov record NCT03124511. Inclusion in this directory is not an endorsement.